Postinflammatory hyperpigmentation - Hîperpîgmentasyona Postinflammatory
Hîperpîgmentasyona Postinflammatory (Postinflammatory hyperpigmentation) rewşek çermî ye ku piştî iltîhaba çermê, bi zêdebûna rengdêra di çerm de tê xuyang kirin. Hîperpîgmentasyona postinflammatory (postinflammatory hyperpigmentation) dikare ji ber dirêjbûna tavê, iltîhaba, an birînên çermên din, tevî yên ku bi pîrzîkan ve girêdayî ne, çêbibe. Kesên ku rengê çermê wan tarîtir in, bi gelemperî bi tîrêjên zêde yên tavê re meyla hîperpîgmentasyonê hene.
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) pirsgirêkek çermê ye ku pir caran piştî iltîhaba çerm an birîndarbûnê çêdibe. Meyldar e ku demek dirêj bidome û di mirovên ku rengê çermê wan tarî ye (Fitzpatrick skin types III–VI) de xerabtir e. Her çend pir caran xwe baştir dibe, ev dikare demek dirêj bike, ji ber vê yekê dermankirin pir caran ji bo demek dirêj hewce ye. Tevlihevkirina dermanên cûda çêtirîn dixebite.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation encamek hevpar a iltîhabê çermê ye. Ew bi giranî û pir caran bandorê li kesên ku çermê tarî hene dike. Lêkolîn nîşan dide ku postinflammatory hyperpigmentation di sedemên sereke de ye, û ev dikare ji ber ku mirovên bi rengê çermê tarîtir têne dîtin, lê ne tenê ji bo dermatolojîkê. Dermankirina zû ji bo çareserkirina postinflammatory hyperpigmentation girîng e; bi gelemperî, ew bi birêvebirina rewşa destpêkê ya înflamatuar dest pê dike. Rêza yekem a dermankirinê bi karanîna ajanên topkî yên ku çerm û tavê ronî dikin, ji bo parastina çermê, tê bikaranîn. Van ajan, mîna hydroquinone, azelaic acid, kojic acid, arbutin, û licorice extract, dikarin pigmentasyona zêde kêm bikin. Wekî din, retinoids, mequinol, ascorbic acid, niacinamide, N‑acetyl glucosamine, û soy jî wekî ajanên depîgmentkirinê têne bikar anîn; hemû wan di dermaçûnên nû de têne bikaranîn. Her çend dermankirinên topkî bi gelemperî ji bo hîperpîgmentasyona asta rûkê bandorê dikin, dibe ku prosedurên (laser, chemical peel) ji bo dozên serhêl hewcedar bin. Girîng e ku meriv bi van dermanan re hişyariyê bikar bîne da ku ji acizbûn û xerabiyê ya postinflammatory hyperpigmentation dûr nebe.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
